Intravenous Recombinant Human Prourokinase for Acute Medium Vessel Occlusion 4.5-24 Hours After Ischemic Stroke
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 616 participants.
Also called NCT07776873
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 616 participants
- Registry
-
NCT07776873
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- China
- Registry status
- Recruiting
Technical summary
Registry record NCT07776873. Randomized; single masking; primary purpose treatment. Start 2026-10-06 (actual); primary completion 2029-06-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Intravenous Recombinant Human Prourokinase for Acute Medium Vessel Occlusion 4.5-24 Hours After Ischemic Stroke
- Acronym
- HOPE-MeVO
- Condition
- Acute Ischemic Stroke
- Intervention (Drug)
- Recombinant Human Prourokinase for Injection (rhPro-UK)
- Intervention (Other)
- Standard medical treatment (SMT)
- Lead sponsor
- The First Affiliated Hospital of Anhui Medical University
Record details
- Record id
cardio:ct-nct07776873- Content hash
9724301914fe99f32dca328902e554a194d0117d81c39f586af72c5c15244f75